{"id":829,"date":"2021-02-12T09:16:32","date_gmt":"2021-02-12T08:16:32","guid":{"rendered":"https:\/\/ago-ovar.de\/profile\/open-trials\/"},"modified":"2026-04-08T14:34:26","modified_gmt":"2026-04-08T12:34:26","slug":"open-trials","status":"publish","type":"page","link":"https:\/\/ago-ovar.de\/en\/profile\/open-trials\/","title":{"rendered":"Open Trials"},"content":{"rendered":"

[et_pb_section fb_built=”1″ specialty=”on” _builder_version=”4.16″ background_color=”#e0edf9″ global_colors_info=”{}”][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”4.16″ custom_padding=”||13px|||” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Open Trials<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” header_2_font_size=”24px” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Ovary<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.19.5″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 27 \/ WoO<\/h3>\n

Window-of-opportunity proof-of-concept, non-randomized, open-label, phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2023\/05\/AGO-OVAR-27_WoO_Synopsis_V07F_2023-02-27.pdf” url_new_window=”on” button_text=”DOWNLOAD AGO-OVAR 27 SYNOPSIS” _builder_version=”4.20.2″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 28<\/h3>\n

Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial)<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2025\/07\/AGO-OVAR-28_Synopse_DE_V04F_2025-05-22_clean.pdf” url_new_window=”on” button_text=”DOWNLOAD AGO-OVAR 28 German synopsis” _builder_version=”4.27.4″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.44 \/ GLORIOSA<\/h3>\n

Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR\u03b1-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2025\/03\/AGO-OVAR-2.44-GLORIOSA_Synopse-deutsch.pdf” url_new_window=”on” button_text=”DOWNLOAD AGO-OVAR 2.44 German synopsis” _builder_version=”4.27.4″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.27.4″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.46 \/ RAMP 301<\/h3>\n

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)<\/p>\n

https:\/\/clinicaltrials.gov\/study\/NCT06072781<\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.27.4″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR 2.48 \/ RAINFOL-OV2<\/h3>\n

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator\u2019s Choice in Patients with Platinum Resistant Ovarian Cancer<\/p>\n

https:\/\/clinicaltrials.gov\/study\/NCT06619236<\/a><\/p>\n

 <\/p>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ custom_padding=”52px|||||” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” header_2_font_size=”24px” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Endometrium \/ Vulva \/ Cervix<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”4.8%|6%|4.8%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-VULVA 1 \/ PIERCE<\/h3>\n

Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy\u00a0(PIERCE)<\/p>\n

 <\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2025\/07\/AGO-VULVA1_Synopsis_V02F_2024-09-17_GER.pdf” url_new_window=”on” button_text=”DOWNLOAD AGO-VULVA 1\/PIERCE German synopsis” _builder_version=”4.27.4″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ custom_padding=”52px|||||” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” header_2_font_size=”24px” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n

Surgical and translational issues<\/h2>\n

[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.0″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

AGO-OVAR OP.11 \/ STREAM I<\/h3>\n

Evaluation of preoperative clinical and translation selection criteria for cytoreductive surgery in endometrial cancer – A retrospective multicenter trial with an accompanying translational project<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2025\/04\/AGO-OP.11_ENGOT-en22_STREAM-I_Synopse_V02F_2024-03-11_EN.pdf” url_new_window=”on” button_text=”DOWNLOAD STREAM I English synopsis” _builder_version=”4.27.4″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.6″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n

TUBA-WISP-II<\/h3>\n

TUBectomy with delayed oophorectomy as Alternative for risk-reducing salpingo-oophorectomy in high-risk Women to assess the Safety of Prevention: TUBA-WISP II<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2026\/04\/TUBA-WISP-II_Synopse_V01F_2025-03-11.pdf” url_new_window=”on” button_text=”DOWNLOAD TUBA-WISP-II German synopsis” _builder_version=”4.27.6″ custom_button=”on” button_text_size=”18px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_sidebar area=”et_pb_widget_area_1″ show_border=”off” admin_label=”Seitenleiste” _builder_version=”4.16″ header_text_color=”#000000″ body_font=”|700|||||||” body_text_color=”#ef5b21″ background_color=”rgba(255,255,255,0.6)” background_enable_color=”off” min_height=”257px” custom_padding=”8%|4%|4%|8%|false|false” saved_tabs=”all” global_colors_info=”{}”][\/et_pb_sidebar][\/et_pb_column][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

Open TrialsOvaryAGO-OVAR 27 \/ WoO Window-of-opportunity proof-of-concept, non-randomized, open-label, phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery in histologically proven high-grade epithelial ovarian cancer (EOC)  AGO-OVAR 28 Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":792,"menu_order":50,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-829","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/comments?post=829"}],"version-history":[{"count":71,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/829\/revisions"}],"predecessor-version":[{"id":2505,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/829\/revisions\/2505"}],"up":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/792"}],"wp:attachment":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/media?parent=829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}